Interius BioTherapeutics is an early-stage biotechnology company focused on expanding the potential of cell and gene therapy by developing next generation delivery technology, based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.

Interius BioTherapeutics

Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.

BrightEdge Fund

OUP (Osage University Partners)

Penn Medicine

Penn Medicine Co-Investment Program

Pfizer Venture Investments

The Mark Foundation for Cancer Research

Quan Capital

RA Capital Management

Cormorant Asset Management

Agent Capital

Logos Capital

Team Interius ‘Turned It Red’ in recognition of Blood Cancer Awareness Month by hosting dinner for 60+ patients and caregivers at American Cancer Society's Hope Lodge in Philadelphia!

Because nothing says ‘comfort’ like a homecooked meal! 

From baked ziti and roasted chicken to brownies and a listening ear, our team showed up to serve!

It was a very rewarding experience for the Interians who participated and were able to visit with guests over dinner.

We are so very proud of our team and this initiative!

Summer 2024 took Interius to Citizens Bank Park!  

What a great time for the team to spend quality time together outside of work!  A great game and knock-out night spent cheering on The Phillies with friends & family!

Special shout out to Isabel Sampson-Mapp of the Netter Center for Community Partnerships at the University of Pennsylvania for connecting us with new friends from our West Phila community to share the game with and for facilitating so many opportunities throughout the year for Interius to be a good neighbor!

Go team Interius! And Go Phils!

Tyler Menichiello, thank you for the shoutout to our Senior Director of Analytical Development, Jim Richardson! Jim moderated a panel and Elaine Youngman presented at the 16th Annual Bioprocessing Summit, highlighting Interius BioTherapeutics' deep expertise in complex CMC and analytics matters in the advanced therapies field with an eye on cost, practical solutions, and interactions with regulators.

Glad to join the conversation at BioTechX USA these past couple of days in Philadelphia. Proud of the Interius BioTherapeutics team for sharing deep insights into IT systems, data capture, storage and architecture, and analytics workflows in support of rapid advancement of our therapeutic programs.

As we prepare for a big year-end, Team Interius took some time to kick back, relax, and enjoy the summer sun!

We hope everyone else is keeping it cool and groovy this summer too! ✌

An excellent article, which interviewed our CEO Philip R. Johnson, MD, describes Interius BioTherapeutics as "one of the most advanced companies in this space". Thank you, Nature Magazine and Asher Mullard for recognizing Interius's progress and unique approach to in vivo CAR T therapy. We look forward to clinical data emerging over the next year and bringing important advancements to the field.

COM:INTERIUSBIO

Interius BioTherapeutics